Oxygenta Pharmaceutical Faces 7-Day Manufacturing License Suspension for Four Key Drugs

Oxygenta Pharmaceutical Limited , a subsidiary of Virupaksha Organics Limited, has encountered a significant regulatory setback. The company received a seven-day suspension order for its manufacturing license from the Drugs Control Administration (DCA), Telangana, affecting the production of four crucial drugs.

Suspension Details

The suspension, which began on October 21, 2025, impacts the manufacturing of the following products:

Etoricoxib
Vildagliptin
Lacosamide
Telmisartan

This action follows violations of certain rules under the Drugs and Cosmetics Act, 1940 and Rules 1945, as reported by the Drugs Inspector.

Financial Impact

The company estimates a potential revenue loss of Rs. 20.00 lakhs during the suspension period. This figure underscores the immediate financial implications of the regulatory action on Oxygenta Pharmaceutical's operations.

License Details

Aspect	Details
License Number	10/MD/AP/2013/B/G
Valid Until	April 23, 2028
Suspension Period	7 days from October 21, 2025
Issuing Authority	Deputy Director, DCA, Nizamabad & Licensing Authority, Government of Telangana

While the manufacturing license remains valid until April 23, 2028, the permission for the specified products is temporarily suspended.

Regulatory Compliance

The suspension order was issued under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates the disclosure of material information pertaining to actions taken by regulatory authorities against listed entities.

Oxygenta Pharmaceutical Limited has promptly disclosed this development to the BSE Limited, demonstrating its commitment to regulatory compliance and transparency.

Looking Ahead

The seven-day suspension poses a short-term challenge for Oxygenta Pharmaceutical. The company's ability to address the cited violations and swiftly resume production of these key drugs will be crucial in minimizing the impact on its operations and financial performance.

Investors and stakeholders will likely be watching closely to see how the company navigates this regulatory hurdle and implements measures to prevent similar incidents in the future.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.82%	-8.13%	-11.02%	-54.00%	-38.51%	+154.47%

Oxygenta Pharmaceutical Limited (Scrip: 524636) has received approval from the BSE Limited (BSE) for the reclassification of four individuals from the "Promoter/Promoter Group" category to the "Public" category. This development marks a significant change in the company's shareholding structure.

Key Details of the Reclassification

The BSE granted its no-objection through a letter dated October 16, 2025, in response to the company's application submitted on August 29, 2025. The individuals to be reclassified are:

Sr. No.	Name of Promoter(s) / Promoter(s) Group
1.	SAI SUDHAKAR VANKINENI
2.	SNIGDHA VANKINENI
3.	SUMANTH SIMHA VANKINENI
4.	JHANSI RANI VANKINENI

Next Steps for Oxygenta Pharmaceutical

Following this approval, Oxygenta Pharmaceutical Limited is required to take several important steps:

Call a shareholders' meeting to seek approval for the reclassification.
Ensure compliance with the requirements of Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Make subsequent relevant disclosures of material events related to this reclassification.

The company's Company Secretary & Compliance Officer, Kumkum Bajaj, confirmed that Oxygenta Pharmaceutical will proceed with all necessary steps in accordance with regulatory requirements.

This reclassification may impact the company's shareholding structure and could be of interest to investors and market analysts tracking Oxygenta Pharmaceutical Limited's stock.